125 related articles for article (PubMed ID: 10707115)
1. Dose independent pharmacokinetics of caffeine after intravenous administration under a chronic food-limited regimen.
Smith C; Ma F; Lau CE
Drug Metabol Drug Interact; 1999; 15(1):83-96. PubMed ID: 10707115
[TBL] [Abstract][Full Text] [Related]
2. Effects of rutaecarpine on the metabolism and urinary excretion of caffeine in rats.
Noh K; Seo YM; Lee SK; Bista SR; Kang MJ; Jahng Y; Kim E; Kang W; Jeong TC
Arch Pharm Res; 2011 Jan; 34(1):119-25. PubMed ID: 21468923
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of caffeine in the oestrogen-implanted ovariectomized ewe.
Pollard I; Williamson S; Downing J; Scaramuzzi R
J Vet Pharmacol Ther; 1996 Apr; 19(2):113-7. PubMed ID: 8735418
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine.
Zandvliet AS; Huitema AD; de Jonge ME; den Hoed R; Sparidans RW; Hendriks VM; van den Brink W; van Ree JM; Beijnen JH
Basic Clin Pharmacol Toxicol; 2005 Jan; 96(1):71-9. PubMed ID: 15667599
[TBL] [Abstract][Full Text] [Related]
5. Effects of the aqueous extract from Salvia miltiorrhiza Bunge on caffeine pharmacokinetics and liver microsomal CYP1A2 activity in humans and rats.
Wang X; Yeung JH
J Pharm Pharmacol; 2010 Aug; 62(8):1077-83. PubMed ID: 20663043
[TBL] [Abstract][Full Text] [Related]
6. Effects of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on rat CYP1A2 expression and metabolism of model CYP1A2 probe substrates.
Wang X; Lee WY; Or PM; Yeung JH
Phytomedicine; 2009 Aug; 16(8):712-25. PubMed ID: 19403289
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of theophylline, theobromine and paraxanthine in the fetal rat brain following a single oral dose of caffeine.
Wilkinson JM; Pollard I
Brain Res Dev Brain Res; 1993 Oct; 75(2):193-9. PubMed ID: 8261611
[TBL] [Abstract][Full Text] [Related]
8. Oral and IP caffeine pharmacokinetics under a chronic food-limitation condition.
Lau CE; Ma F; Falk JL
Pharmacol Biochem Behav; 1995 Feb; 50(2):245-52. PubMed ID: 7740064
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics.
Perera V; Gross AS; Xu H; McLachlan AJ
J Pharm Pharmacol; 2011 Sep; 63(9):1161-8. PubMed ID: 21827488
[TBL] [Abstract][Full Text] [Related]
10. A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects.
Thai C; Tayo B; Critchley D
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1279-1289. PubMed ID: 33951339
[TBL] [Abstract][Full Text] [Related]
11. Multiple dose pharmacokinetics of caffeine administered in chewing gum to normal healthy volunteers.
Syed SA; Kamimori GH; Kelly W; Eddington ND
Biopharm Drug Dispos; 2005 Dec; 26(9):403-9. PubMed ID: 16158445
[TBL] [Abstract][Full Text] [Related]
12. Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine.
Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM
J Clin Pharmacol; 1999 Mar; 39(3):252-9. PubMed ID: 10073324
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of pharmacokinetic interaction of aphobazole with CYP1A2 drug-substrate in experiments].
Novitskaia IaG; Litvin AA; Viglinskaia AO; Zherdev VP
Eksp Klin Farmakol; 2013; 76(6):30-3. PubMed ID: 24003488
[TBL] [Abstract][Full Text] [Related]
14. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.
Kinzig-Schippers M; Fuhr U; Zaigler M; Dammeyer J; Rüsing G; Labedzki A; Bulitta J; Sörgel F
Clin Pharmacol Ther; 1999 Mar; 65(3):262-74. PubMed ID: 10096258
[TBL] [Abstract][Full Text] [Related]
15. Reduction in non-glomerular renal clearance of the caffeine metabolite 1-methylxanthine by probenecid.
Rengelshausen J; Göggelmann C; Burhenne J; Riedel KD; Mikus G; Walter-Sack I; Haefeli WE
Int J Clin Pharmacol Ther; 2007 Aug; 45(8):431-7. PubMed ID: 17725176
[TBL] [Abstract][Full Text] [Related]
16. Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women.
Zaigler M; Rietbrock S; Szymanski J; Dericks-Tan JS; Staib AH; Fuhr U
Int J Clin Pharmacol Ther; 2000 May; 38(5):235-44. PubMed ID: 10839467
[TBL] [Abstract][Full Text] [Related]
17. Caffeine in apnoeic Asian neonates: a sparse data analysis.
Lee HS; Khoo YM; Chirino-Barcelo Y; Tan KL; Ong D
Br J Clin Pharmacol; 2002 Jul; 54(1):31-7. PubMed ID: 12100222
[TBL] [Abstract][Full Text] [Related]
18. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma.
Perera V; Gross AS; McLachlan AJ
Biomed Chromatogr; 2010 Oct; 24(10):1136-44. PubMed ID: 20853468
[TBL] [Abstract][Full Text] [Related]
19. The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians.
Akinyinka OO; Sowunmi A; Honeywell R; Renwick AG
Eur J Clin Pharmacol; 2000 May; 56(2):159-65. PubMed ID: 10877011
[TBL] [Abstract][Full Text] [Related]
20. Chronic effects of xanthines on levels of central receptors in mice.
Shi D; Daly JW
Cell Mol Neurobiol; 1999 Dec; 19(6):719-32. PubMed ID: 10456233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
